Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of ageing and increase human longevity, announces that David Ellam has joined its Executive Management Team as Chief Financial Officer.
David has almost 20 years of experience within life science companies. He has previously occupied several senior finance roles within both US & UK publicly owned life science companies, most recently as CFO at Silence Therapeutics Plc (2016-2019), Senior EUMEA Finance Director at BioMarin Pharmaceuticals Inc. (2010 to 2016),CFO of Plethora Solutions Plc (2008-2009) and as Group Financial Controller at Ark Therapeutics Plc (2001-2008).
Greg Bailey, CEO of Juvenescence, commented:
Juvenescence has had a tremendously successful initial phase of growth, identifying a wide range of therapeutics and technologies with strong potential to modify how people age, creating a Juvenescence ecosystem of new ventures and collaborations, and raising well over $110M in early stage funding. The next phase to support this ecosystem involves strengthening our leadership team and providing enhanced support to our portfolio companies so that we can continue to deliver on the promise of these therapeutics and technologies. I am delighted that David has joined Juvenescence and look forward to working together to further develop our infrastructure & corporate governance, as we plan and execute the next stage of our business growth, and potentially a listing on an international exchange.
David Ellam commented: I am excited to join Juvenescence at such an important inflection point for the company as the life sciences industry wakes up to the wealth of scientific discoveries into human longevity. Juvenescence is a unique nexus of classical drug development, regenerative medicine and AI with a mission to help people live longer, healthier lives.
About Juvenescence, Ltd.
Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging.